The trajectory of companies tied to the drug's past presents a intricate investment picture . While the initial success generated substantial profits , generic competition have significantly eroded revenue. Investing in associated pharmaceutical companies now requires a careful assessment of proprietary safeguards, evolving healthcare trends , and